The nation of Zimbabwe has declined a substantial American healthcare agreement worth 367 million US dollars (£272m) over five years due to the United States' request for confidential information.
This rejection was revealed following a government memo dated December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesman later clarified that the US was requesting biological samples for research and commercial purposes but refused to share the benefits from any future medical innovations.
"We will now turn to the difficult and regrettable task of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had provided more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for continued negotiations to reach a deal acceptable to both sides so the nation's critical HIV programme can continue.
Broader Context
Zimbabwe's decision follows a comparable situation in Kenya, where a court halted a similar health funding agreement following concerns were filed about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump stated its spending was "inefficient" and his government was pursuing direct bilateral agreements to enhance openness and accountability.
As per reports, Sixteen nations in Africa have to date agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation could have provided immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment through American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no corresponding promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"Effectively, our country would provide the basic resources for scientific discovery without any certainty that the final treatments would be accessible to our people if a future health crisis emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its push of bilateral deals were upending structures previously set up via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to manage future global health emergencies.
"This system is designed to ensure that when a nation provides its information, the resulting advantages – including medicines and cures – are shared equitably, not monopolised solely by those with the funds to develop them."
These objections over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how future collaboration could be arranged in a way that respects the sovereignty and interests of both nations."
Medical Community Reaction
A leading public health body stated it recognised the government's concerns, but suggested that negotiations need to persist given that a large portion of the nation's Aids initiatives relied on foreign aid.
"In cases where technical issues exist, including those involving information security or implementation frameworks, these can often be resolved through detailed discussion and mutually agreed protections," it said.
The halted deal highlights the complex debate between accepting vital foreign assistance and protecting a country's data in an increasingly data-driven world.